Real-world experience of the feasibility and tolerability of the 2:1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia

Megan Crumbaker, Howard Gurney, Alex Guminski, Shirley Wong, Dhanusha Sabanathan, Nick Pavlakis

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Article numberabs#209
Pages (from-to)47
Number of pages1
JournalAsia-Pacific Journal of Clinical Oncology
Volume12
Issue numberS3
DOIs
Publication statusPublished - Jul 2016
EventANZUP Annual Scientific Meeting: Expanding our Horizons - Brisbane, Australia
Duration: 10 Jul 201612 Jul 2016

Cite this